Clinical trials: Refractory Neoplasm
DLBCL
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma.
- Trial name
- NCT04300803
- Testing
- Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
- Sponsor
- MorphoSys AG
Small Cell Lung Carcinoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
- Trial name
- NCT06799286
- Testing
- BMS-986489
- Where
- 5 sites in China
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma (MM)
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
- Trial name
- NCT04649073
- Testing
- OPC-415
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
B-cell Non Hodgkin Lymphoma, Richter's Transformation
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
- Trial name
- NCT03778073
- Testing
- Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- TG Therapeutics, Inc.
Hematologic Malignancy, Acute Myeloid Leukemia
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT03795779
- Testing
- CLL1-CD33 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.
- Trial name
- NCT04948788
- Testing
- SHR1459 ；YY-20394, Gemcitabine-Oxaliplatin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Relapse/Refractory Mantle Cell Lymphoma
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
The primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially available…
- Trial name
- ZUMA-18 (NCT04162756)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 9 sites in United States
- Sponsor
- Kite, A Gilead Company
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT01398462
- Testing
- CWP232291
- Where
- 5 sites in United States, South Korea
- Volunteers
- 69 people
- Sponsor
- JW Pharmaceutical
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in…
- Trial name
- NCT04434469
- Testing
- RO7297089
- Where
- 10 sites in Australia, Belgium and 2 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor, Adult Disease
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Adult Disease, Lung Cancer
- Trial name
- ANV419-001 (NCT04855929)
- Testing
- ANV419, Ipilimumab
- Where
- 5 sites in Spain, Switzerland and 1 more
- Volunteers
- 55 people
- Sponsor
- Anaveon AG
Non-Hodgkin's Lymphoma
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
- Trial name
- NCT00042666
- Testing
- LY317615
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
- Trial name
- ELARA (NCT03568461)
- Testing
- tisagenlecleucel
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Mesothelioma, BAP1 Loss of Function
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally.
- Trial name
- NCT02860286
- Testing
- Tazemetostat
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Epizyme, Inc.
Metastatic Colorectal Cancer
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
Researchers are collecting more information to improve treatment of metastatic colorectal cancer (mCRC) with regorafenib. Metastatic colorectal cancer (mCRC) is a cancer that starts in the large bowel and involves the rectum (the…
- Trial name
- RE-SEARCH (NCT04920422)
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Bayer
Relapsed/Refractory AML
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese…
- Trial name
- NCT04839341
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Apollomics Inc.
Acute Myeloid Leukemia
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
- Trial name
- NCT05471323
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Neoplasms, Prostatic Neoplasms
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously…
- Trial name
- TROPIC (NCT00417079)
- Testing
- cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone
- Where
- 26 sites in United States, Argentina and 24 more
- Volunteers
- 755 people
- Sponsor
- Sanofi
Multiple Myeloma
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment…
- Trial name
- NCT01002248
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Where
- 86 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AEterna Zentaris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.